Clinical Trials
66 trialsA Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
DESCENT-1
A2 Biotherapeutics Inc.
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
BASECAMP-1
A2 Biotherapeutics Inc.
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
SELECT-2CAR
Beijing Biotech
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
ARC-25
Arcus Biosciences, Inc.
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
MK-4700-001
Merck Sharp & Dohme LLC
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
PRO1107 in Patients With Advanced Solid Tumors
Genmab
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
ELEPHAS-05
Elephas
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics Ltd
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
ON-5001
OncoNano Medicine, Inc.
TASTY-steering
University Medical Center Groningen
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NEUTROFLOW
OncoHost Ltd.
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
AGADIR
Institut Bergonié
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
ModiFY
Scancell Ltd